Albemarle Corp. vs GeneDx Holdings Corp — how do they compare? Albemarle Corp. trades at $128.26 (market cap $15.27B), while GeneDx Holdings Corp trades at $82.15 (market cap $2.44B). The key difference: Albemarle Corp. is far larger — about 6.3× GeneDx Holdings Corp's market cap, and Albemarle Corp. pays a 1.27% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| ALB | WGS | |
|---|---|---|
Market Cap | $15.27B | $2.44B |
Sector | Basic Materials | Technology |
52-Week High | $215.62 | $167.51 |
52-Week Low | $72.58 | $34.51 |
Enterprise Value | $17.75B | $2.48B |
Dividend Yield | 1.27% | — |
Signals from Pluang's Aura AI — not financial advice
ALB trades at $128.21, down 2.29% today, amid a mixed technical picture with bullish moving averages but overbought RSI signals. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.75, driven by improved lithium pricing and cost savings. Revenue for 2025 was $5.14B, though net income remained negative at -$510.63M. Analyst consensus is a Buy with a $184.50 price target, reflecting optimism for recovery.
Outlook is cautiously optimistic as lithium demand supports earnings growth, but Q3 guidance warns of sequential declines. Key risks include volatile lithium prices and execution challenges. The stock offers potential upside to analyst targets if operational improvements continue, but investors face margin pressure and macroeconomic headwinds.
GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.
Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.
Trailing returns across standard periods
Albemarle is the world's largest lithium producer. Our outlook for robust lithium demand is predicated upon increased demand for electric vehicle batteries. Albemarle produces lithium from its salt brine deposits in Chile and the U.S. and its hard rock joint venture mines in Australia. Albemarle is also a global leader in the production of bromine, used in flame retardants. The company is also a major producer of oil refining catalysts.
Read more on ALB →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →